sar425899 sanofi dual glp-1 glucagon agonist Current GLP-1, GIP, and receptor co-agonists in development The current significance and prospects
Description
These drugs work by lowering blood glucose levels, which helps patients with type 2 diabetes manage their metabolisms and hunger
designed a nicotinic acid derivative as a new DPP-4 inhibitor (115)
18.2%) and a higher occurrence of hypertension (80.9% vs
503As can now source drugs from 503Bs and dispense them based on an individual prescription
